You get your lab results. Your total cholesterol is 210 mg/dL. Your doctor says it's a little high and suggests you watch your diet. You leave the office worried about eggs and butter — and completely unaware that your actual cardiovascular risk may be very different from what that single number implies.
This happens thousands of times a day across America. And it happens because cholesterol medicine has been simplified to the point of distortion. The story of cholesterol and heart disease is real — but it's far more nuanced than the version most patients receive. As a preventive cardiologist, I spend a significant portion of each consultation correcting misconceptions that have been years in the making.
Let's go through the most persistent myths — and what the evidence actually says.
Myth 1: Total Cholesterol Is the Number That Matters
Your total cholesterol number tells you your heart disease risk.
Total cholesterol is a blunt instrument. It adds together HDL (protective), LDL (atherogenic), VLDL, and other fractions into a single figure that can be misleading in either direction. A patient with a total cholesterol of 240 who has very high HDL and low triglycerides may have far lower cardiovascular risk than a patient with a total cholesterol of 175 with low HDL and high triglycerides.
Total cholesterol became the primary metric in an era when more precise measurement wasn't easily available. We have long since surpassed that era — but the framing persists in public health messaging, life insurance questionnaires, and unfortunately many primary care conversations.
What matters is the composition of that total: how much is LDL, how much is HDL, what are the triglycerides, and — most importantly — what is the particle count. More on that shortly.
Myth 2: HDL Is Always "Good" and More Is Always Better
A high HDL means you're protected from heart disease.
HDL — high-density lipoprotein — is associated with cardiovascular protection at moderate levels. But at very high levels (above 80–90 mg/dL), this relationship breaks down. Multiple large trials of drugs designed to raise HDL showed no reduction in cardiovascular events, and some showed harm. Elevated HDL from genetic variants known as CETP mutations is not cardioprotective. The function of HDL matters as much as the quantity.
HDL-mediated reverse cholesterol transport — the process of removing cholesterol from arterial walls and returning it to the liver — is the mechanism that confers protection. Dysfunctional HDL can be present in high quantities yet perform this function poorly. This is why a patient with an HDL of 95 mg/dL is not necessarily protected, and why HDL alone should never be used to reassure patients that their lipid risk is managed.
Myth 3: LDL Cholesterol and LDL Particle Number Are the Same Thing
Your LDL-C number tells you how much atherogenic cholesterol is in your blood.
LDL-C (LDL cholesterol) measures the amount of cholesterol carried inside LDL particles. LDL-P (LDL particle number) counts the actual number of particles. These are not the same. A patient with the same LDL-C can have dramatically different LDL-P depending on particle size and composition. Small, dense LDL particles carry less cholesterol each — so LDL-C can be "normal" while LDL-P is very high.
This distinction matters because it is the particle itself — not its cholesterol cargo — that penetrates the arterial wall and initiates plaque formation. When LDL-C and LDL-P disagree, LDL-P is the stronger predictor of cardiovascular events. This discordance is particularly common in patients with insulin resistance, metabolic syndrome, or elevated triglycerides — precisely the patients in whom standard lipid panels most often mislead.
ApoB, the protein on the surface of every atherogenic particle, offers an equally precise alternative to LDL-P — and is widely available on standard lab panels. More on ApoB in a separate post.
Myth 4: A "Normal" LDL Means Your Cholesterol Is Fine
If your LDL is under 130 (or 100), you don't need to worry about your cholesterol.
The definition of "normal" LDL has been historically set by population averages in Western societies — populations with high rates of cardiovascular disease. Populations with lifelong LDL levels of 50–70 mg/dL essentially never develop atherosclerosis. Mendelian randomization studies show that the relationship between LDL and cardiovascular risk is continuous: lower is better, with no lower threshold observed in the evidence.
The concept of a "normal" LDL in cardiovascular medicine should be replaced by a concept of an optimal LDL — one informed by your individual lifetime risk. A 45-year-old with familial hypercholesterolemia and a family history of premature heart disease has a very different optimal LDL target than a 68-year-old with no risk factors.
Myth 5: Dietary Cholesterol Is the Main Driver of Blood Cholesterol
Eating cholesterol-rich foods raises your blood cholesterol.
For most people, dietary cholesterol has a modest effect on blood cholesterol levels. The liver compensates for increased dietary intake by producing less cholesterol endogenously. What has a much larger effect on atherogenic lipoproteins is dietary saturated fat — which upregulates hepatic LDL production — and refined carbohydrates, which drive triglyceride synthesis and the production of small, dense LDL particles.
Eggs — long demonized for their cholesterol content — are a perfect example of this disconnect. For most people without familial hypercholesterolemia or specific genetic variants (APOE4), moderate egg consumption does not meaningfully raise cardiovascular risk. The dietary pattern matters far more than any single food. A diet high in ultra-processed foods, refined grains, and sugar is far more atherogenic than one that includes eggs alongside vegetables, legumes, and healthy fats.
Myth 6: Statins Are Just Lowering a Number — Not Changing Outcomes
Statins reduce LDL but don't actually prevent heart attacks.
This claim, prominent in certain wellness communities, is contradicted by some of the largest and most rigorous clinical trials in cardiovascular medicine. Meta-analyses of statin trials involving hundreds of thousands of patients consistently show significant reductions in major cardiovascular events — heart attacks, strokes, and cardiovascular death — proportional to the degree of LDL lowering achieved.
Statins do have real side effects for a minority of patients, particularly myopathy and new-onset diabetes at higher doses. These deserve honest discussion and careful monitoring. But the evidence for their benefit in appropriate patients — those with established cardiovascular disease or elevated lifetime risk — is among the most robust in all of medicine.
The appropriate question is not "should I avoid statins" but "am I the right patient for a statin, and if so, at what intensity?" That question should be answered with a full lipid panel, ApoB or LDL-P measurement, coronary artery calcium scoring where relevant, and a genuine shared decision-making conversation.
What a Complete Lipid Assessment Actually Looks Like
Beyond the Standard Panel
A standard lipid panel ordered at your annual physical answers perhaps 40% of the clinical question. The rest requires either additional biomarkers or a structural imaging test like the coronary artery calcium score — which can reveal significant atherosclerosis in patients with ostensibly reassuring labs, and near-zero risk in patients whose numbers look elevated.
What I Do Differently
At ElinMed, every lipid evaluation includes ApoB and Lp(a) at minimum. For patients with borderline or discordant results, or those with metabolic syndrome, we extend to a full NMR lipoprotein profile. Where treatment decisions remain uncertain after biomarkers, we incorporate CAC scoring to directly interrogate the arterial wall. Cholesterol numbers inform; arterial imaging decides.Cholesterol is not the enemy. Uncontrolled, progressive atherosclerosis is. The path to preventing it runs through precision measurement, individual risk stratification, and a willingness to look beyond the number on the standard lab report.
Get a Complete Lipid Assessment
Standard panels miss the picture. A preventive cardiology consultation at ElinMed includes ApoB, Lp(a), and a full risk discussion — so you know exactly where you stand.
Book a Visit